McCarter & English LLP
McCarter & English LLP’s renowned IP team has 130 IP lawyers, technical specialists and patent agents with industry experience and graduate degrees in engineering and life sciences (including 30 PhDs and an MD). We draw on our experience in patent prosecution and litigation, technology licensing and transfer, corporate transactional, US Food and Drug Administration regulation and general business matters to assist clients in building and managing patent portfolios that best serve their strategic business goals, whether developing patent portfolios for pre-clinical products of early-stage companies or blockbuster biologics for major pharmaceutical companies.
We work with client patent committees, R&D and product development groups, laboratory and research teams, engineers and scientists to determine appropriate patentable subject matter and to devise patent prosecution strategies for maximising US and international protection.
Members of McCarter’s patent prosecution team have advanced degrees in fields such as molecular biology, cell biology, immunology, biochemistry, microbiology, organic chemistry and inorganic chemistry, and have years of pharmaceutical industry experience – including former scientific and in-house counsel positions – and former patent office examiners well versed in the intricacies of the US Patent and Trademark Office (USPTO).
Our life sciences IP group prosecutes patent applications involving biomarkers, gene therapy, protein formulations, diagnostic assays, crystallography, ribonucleic acid interference, biofuels, genetic engineering, small molecule pharmaceuticals, medical devices, polymer chemistry, formulations and plant biotechnology. We prosecute antibody patents, including human antibodies, humanised antibodies, multi-specific and multivalent antibodies, antibody production and clinical uses of antibodies.
We serve our life sciences clients in all facets of IP development, maintenance and enforcement. Our attorneys are as experienced and innovative when it comes to the development of strategies for protecting critical core technologies as they are in patenting new innovations based on clients’ immediate and long-term business goals. We help some of the biggest names in the biotechnology, pharmaceutical, university and life sciences fields to build and manage complex patent portfolios protecting blockbuster biotech and small molecule drugs and develop global strategic plans.
The America Invents Act has shifted the landscape for patent challenges from the courts to the USPTO. Validity will primarily be decided in the USPTO and then shift to the federal district courts for infringement. Now, a successful challenge or defence requires both experienced patent prosecutors with a significant knowledge of post-grant challenges before the USPTO and experienced trial lawyers for the discovery phase and oral proceedings before the board. We have a proven track record in inter partes re-examination, inter partes review and post-grant review of covered business method patents as both experienced prosecutors and trial lawyers. We have a multitude of active inter partes reviews and covered business method reviews and additional petitions that have already resulted in settlement. Team members have industry and academic expertise in material science, chemistry, biology, physics, engineering and software, and have worked in the most prestigious labs in the United States, Europe and China. Our trial lawyers have decades of experience of high-profile and successful trials and alternative dispute resolution.
An intelligent approach to the pursuit of clients’ business objectives is a hallmark of our litigation practice. McCarter is ranked fourth nationwide as a Go-To Firm for Patent Plaintiffs in 2017 according to Lex Machina’s patent litigation 2017 year-in-review. Our patent litigation team advocates for clients in patent cases, Hatch-Waxman cases and Markman hearings in courts nationwide. Our cases involve pharmaceuticals, biotechnology, medical devices, surgical techniques, chromatography, immunochemical diagnostic devices, electrochemical biosensors, polymer plastics and medical lasers. McCarter combines broad experience in patent cases and IP disputes with a depth of technical and scientific knowledge, a thorough understanding of patent and IP law, experienced mastery of litigation strategy and in-depth trial skills.
Our IP transactions team provides strategic advice to companies in all critical phases of development, from aiding pre-clinical early-stage companies seeking seed funding to structuring joint ventures and acquisitions for major pharmaceutical companies with blockbuster biologics. In coordination with our patent specialists, the team performs due diligence for licensing, acquisitions and funding of companies. This multidisciplinary approach, applied to every aspect of the transaction (deal structure, closing strategies and research, development, manufacturing, marketing and regulatory compliance guidance), results in timely and cost-effective legal services for clients.
McCarter & English LLP
265 Franklin Street
Boston MA 02110
- Elizabeth A Hanley, Partner
- East Brunswick
- New York
- Washington DC
Sample client list
- AbbVie Laboratories
- Berg Pharma LLC
- BioDelivery Sciences International
- Hayward Industries